Part 2: 2024 Hatch-Waxman Year in Review

from Womble Perspectives · host Womble Bond Dickinson

Today, we're zooming in on key cases decided this past year and unpacking their broader implications for the pharmaceutical industry. We’ll look at decisions that refined safe harbor provisions, imposed stricter scrutiny on certain patents, tackled Orange Book listings, and much more. And before we close, we’ll share some insights into what the industry may encounter in 2025, so stick around to the end to hear what to expect in the coming year. Read the full article2024 Hatch-Waxman Year in ReviewAbout the authorsBen BourkeAlexander P. Wharton

Episode metadata supplied by the publisher feed · Published Jan 25, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Part 2: 2024 Hatch-Waxman Year in Review

0:00 6:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Womble Perspectives?

This episode is 6 minutes long.

When was this Womble Perspectives episode published?

This episode was published on January 25, 2025.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Womble Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!